Hendrik Theis

ORCID: 0000-0003-4661-5994
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurological disorders and treatments
  • Parkinson's Disease Mechanisms and Treatments
  • Functional Brain Connectivity Studies
  • Advanced Neuroimaging Techniques and Applications
  • Advanced MRI Techniques and Applications
  • Neurotransmitter Receptor Influence on Behavior
  • Medical Imaging Techniques and Applications
  • Dementia and Cognitive Impairment Research
  • Neural and Behavioral Psychology Studies
  • Genetic Neurodegenerative Diseases
  • Autism Spectrum Disorder Research
  • Cellular transport and secretion
  • Obsessive-Compulsive Spectrum Disorders
  • Radiomics and Machine Learning in Medical Imaging
  • Sexuality, Behavior, and Technology
  • Mental Health Research Topics
  • EEG and Brain-Computer Interfaces
  • Autoimmune Neurological Disorders and Treatments
  • Attention Deficit Hyperactivity Disorder
  • Alzheimer's disease research and treatments
  • Neuroscience and Neuropharmacology Research
  • Conducting polymers and applications
  • Cancer-related cognitive impairment studies
  • Mental Health and Psychiatry
  • Retinal Development and Disorders

University of Cologne
2019-2025

University Hospital Cologne
2019-2025

Forschungszentrum Jülich
2024

University of Brescia
2024

University of Lübeck
2023

University Hospital Schleswig-Holstein
2023

University Hospital Ulm
2023

Klinik und Poliklinik für Neurologie
2020

Impulsive-compulsive behaviours like pathological gambling or hypersexuality are a frequent side effect of dopamine replacement therapy in patients with Parkinson's disease. Multiple imaging studies suggest significant reduction presynaptic transporters the nucleus accumbens to be predisposing factor, reflecting either mesolimbic projections or, alternatively, lower transporter expression per se. Here, we aimed test hypothesis fewer as risk factor by using synthesis capacity proxy...

10.1093/brain/awz007 article EN Brain 2019-01-08

We used a new data-driven methodology to identify set of reference regions that enhanced the quantification SUV ratio second-generation tau tracer 2-(2-([<sup>18</sup>F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine ([<sup>18</sup>F]PI-2620) in group patients clinically diagnosed with 4-repeat tauopathy, specifically progressive supranuclear palsy or cortical basal syndrome. The study found ratios calculated using identified (i.e., fusiform gyrus and crus-cerebellum) were...

10.2967/jnumed.123.265930 article EN cc-by Journal of Nuclear Medicine 2024-04-04

ObjectivesHigher-educated patients with Alzheimer disease (AD) can harbor greater neuropathologic burden than those less education despite similar symptom severity.In this study, we assessed whether observation is also present in potential preclinical AD stages, namely individuals subjective cognitive decline and clinical features increasing likelihood (SCD+). MethodsAmyloid-PET information ([ 18 F]Flutemetamol or [ F]Florbetaben) of SCD+, mild impairment (MCI), were retrieved from the...

10.1212/wnl.0000000000208053 article EN cc-by Neurology 2024-02-20

We tested whether network resilience, quantified by attack tolerance (NAT), is associated with dopamine terminal (DaT) integrity, motor function and lifetime factors in Parkinson's disease (PD). Data from 22 PD patients 39 healthy controls included information on physical activity (PA), cognitive/motor performance, putaminal DaT resting-state fMRI. NAT was assessed at global subnetwork level calculating efficiency upon iterative node removal. Generalized linear-mixed-effects models were used...

10.1101/2025.03.14.643226 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2025-03-17

Anti-IgLON5 disease is a recently discovered neurologic disorder combining autoimmunity and neurodegeneration. Core manifestations include sleep disorders, bulbar symptoms, gait abnormalities, cognitive dysfunction, but other presentations have been reported. Hallmarks are autoantibodies targeting the neuronal surface protein IgLON5, strong human leukocyte antigen system Class II association, brainstem hypothalamus-dominant tau deposits. The purpose of this cohort study was to visualize...

10.1212/wnl.0000000000207870 article EN cc-by-nc-nd Neurology 2023-10-25

Abstract The relative inability to produce effortful movements is the most specific motor sign of Parkinson’s disease, which primarily characterized by loss dopaminergic terminals in putamen. motivation hypothesis suggests that this deficit may not reflect a deficiency control per se, but cost-benefit considerations for effort. For first time, we investigated quantitative effect dopamine depletion on effort disease. A total 21 early-stage, unmedicated patients with disease and 26 healthy...

10.1093/brain/awae214 article EN Brain 2024-06-28

Abstract Clinical, cognitive, and atrophy characteristics depending on sex have been previously reported in Parkinson’s disease (PD). However, though differences cortical gray matter measures early drug naïve patients described, little is known about thickness (CTh) as the advances. Our multi-site sample comprised 211 non-demented PD (64.45% males; mean age 65.58 ± 8.44 years old; duration 6.42 5.11 years) 86 healthy controls (50% 65.49 9.33 old) with available T1-weighted 3 T MRI data from...

10.1038/s41531-024-00686-2 article EN cc-by npj Parkinson s Disease 2024-03-23

Abstract Multi‐site MRI datasets are crucial for big data research. However, neuroimaging studies must face the batch effect. Here, we propose an approach that uses predictive probabilities provided by Gaussian processes (GPs) to harmonize clinical‐based studies. A multi‐site dataset of 216 Parkinson's disease (PD) patients and 87 healthy subjects (HS) was used. We performed a site GP classification using data. The outcomes estimated from this classification, redefined like Weighted...

10.1002/hbm.25838 article EN Human Brain Mapping 2022-03-19

Impulsive-compulsive behaviour (ICB) is a frequently observed non-motor symptom in early Parkinson's disease after initiating dopamine replacement therapy. At the opposite end of motivated spectrum, apathy occurs even before started. The co-occurrence these behavioural conditions raises questions about their relationship and underlying pathophysiological determinants. In previous imaging or genetic studies, both have been associated with limbic dopaminergic system. risk variant Ser9Gly...

10.1038/s41531-023-00596-9 article EN cc-by npj Parkinson s Disease 2023-11-15

Abstract The relative inability to produce effortful movements (akinesia) is the most specific motor sign of Parkinson’s disease. motivation hypothesis suggests that akinesia may not reflect a deficiency in control per se , but cost-benefit considerations for effort. For first time, we investigated quantitative effect dopamine depletion on effort A total 21 patients with disease and 26 healthy controls were included. An incentivized force task was used capture amount participants willing...

10.1101/2024.03.15.585221 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-03-17

Abstract Recent studies in Parkinson's disease (PD) patients reported disruptions dynamic functional connectivity (dFC, i.e., a characterization of spontaneous fluctuations over time). Here, we assessed whether the integrity striatal dopamine terminals directly modulates dFC metrics two separate PD cohorts, indexing dopamine‐related changes large‐scale brain network dynamics and its implications clinical features. We pooled data from disease‐control cohorts reflecting early PD. From...

10.1002/hbm.26776 article EN cc-by-nc Human Brain Mapping 2024-07-03

Abstract Disorders characterised by changes in dopamine (DA) neurotransmission are often linked to the temporal discounting of future rewards. Likewise, pharmacological manipulations DA neuro-transmission healthy individuals modulate discounting, but there is considerable variability directionality reported effects, as enhancements and reductions signalling have been both increases discounting. This may be due meaningful individual differences drug effects and/or false positive findings...

10.1101/2024.08.28.610170 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-08-29

Abstract Hypersexuality in medicated patients with PD is caused by an increased influence of motivational drive areas and a decreased inhibitory control due to dopaminergic medication. In this pilot study, we test newly developed paradigm investigating the medication on brain activation elicited sexual pictures without contextual framing. Twenty hypersexuality were examined fMRI either OFF or ON standardized The consisted priming phase where neutral context was presented. This followed...

10.1007/s00221-022-06397-5 article EN cc-by Experimental Brain Research 2022-06-28

Patients with Parkinson’s disease are highly vulnerable for cognitive decline. Thus, early intervention by means of working memory training (WMT) may be effective the preservation cognition. However, influence structural brain properties, i.e., cortical thickness and volume white matter lesions on responsiveness have not been studied. Here, behavioral neuroimaging data 46 patients disease, 21 whom engaged in home-based, computerized adaptive WMT, was analyzed. While were associated...

10.3233/jpd-230367 article EN cc-by-nc Journal of Parkinson s Disease 2024-01-23

Abstract Introduction Recent studies in Parkinson’s disease (PD) patients reported disruptions dynamic functional connectivity (dFC, i.e., a characterization of spontaneous fluctuations over time). Here, we assessed whether the integrity striatal dopamine terminals directly modulates dFC metrics separate PD cohorts, indexing dopamine-dependent changes large-scale brain network dynamics and its implications clinical features. Methods We pooled data from two cohorts reflecting early PD. From...

10.1101/2024.03.06.583342 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-03-11

Psychotic symptoms and delusional beliefs have been linked to dopamine transmission in both healthy clinical samples are assumed result at least part from perceiving illusory patterns noise. However, the existing literature on role of detecting noise is inconclusive. To address this issue, we assessed effect manipulating dopaminergic neurotransmission pattern perception individuals ( n = 48, 19 female) a double-blind placebo-controlled within-subjects design (see preregistration...

10.1523/eneuro.0465-23.2024 article EN cc-by-nc-sa eNeuro 2024-07-01

In progressive supranuclear palsy (PSP), subcortical tau and cortical perfusion can be assessed using the tracer [18F]PI-2620. We investigated if (globus pallidus internus, dentate nucleus) frontal/limbic correlate in a cohort of 32 PSP patients. Tau regions showed significant negative correlation with limbic cortex. Perfusion frontal was negatively associated both regions, but significance threshold only passed for nucleus. A reason could diaschisis-like phenomenon; that is, lead to reduced...

10.3233/jpd-240210 article EN cc-by-nc Journal of Parkinson s Disease 2024-07-12

Abstract Psychotic symptoms and delusional belief have been linked to dopamine transmission in both healthy clinical samples are assumed result at least part from perceiving illusory patterns noise. However, the existing literature on role of detecting noise is inconclusive. To address this issue, we assessed effect manipulating dopaminergic neurotransmission pattern perception individuals ( n = 48, 19 female) a double-blind placebo-controlled within-subjects design (see preregistration...

10.1101/2023.10.24.563723 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2023-10-27

Abstract Background Alzheimer’s disease (AD) is characterized by the cerebral accumulation of amyloid‐beta (A), tau (T), and progressive neurodegeneration (N). The widely used ATN system, with regard to positron emission tomography (PET) biomarkers, categorizes AD based on mean signal in specific regions interest (ROI). However, this procedure disregards spatial extent pathology neurodegeneration. Here, we propose an alternative quantification volume, i.e., fill states, A, T N (pre)‐clinical...

10.1002/alz.082991 article EN Alzheimer s & Dementia 2023-12-01
Coming Soon ...